Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mk-0533. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 19/20 | 1.00 |
| ▸ | PPARA | Q07869 | 12/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | CYP4X1 | Q8N118 | 1/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | TACR2 | P21452 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mk-0533 SCHEMBL671319 | 1.00 | PPARG (1.00) | PPARGPPARACYP2C9CYP1A2CYP2D6 | |
| Mk-0533 SCHEMBL13384215 | 1.00 | PPARG (1.00) | PPARGPPARACYP2C9CYP1A2CYP2D6 | |
| Mk-0533 SCHEMBL29520455 | 1.00 | PPARG (1.00) | PPARGPPARACYP2C9CYP1A2CYP2D6 | |
| SCHEMBL671320 | 0.94 | PPARG (0.89) | PPARGPPARACYP2C9CYP1A2CYP2D6 | |
| SCHEMBL530540 | 0.94 | PPARG (0.89) | PPARGPPARACYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2599627 | 0.94 | PPARG (0.89) | PPARGPPARACYP2C9CYP1A2CYP2D6 | |
| SCHEMBL14447483 | 0.93 | PPARG (0.87) | PPARGPPARACYP2C9CYP1A2CYP2D6 | |
| SCHEMBL14447496 | 0.93 | PPARG (0.87) | PPARGPPARACYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2901375 | 0.92 | PPARG (0.86) | PPARGPPARACYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2898987 | 0.92 | PPARG (0.86) | PPARGPPARACYP2C9CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2464228-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-2676960-B1 | Combination drugs comprising aminotetrahydropyrans as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-2676961-B1 | Combination drugs comprising aminotetrahydropyrans as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-2760855-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AS WELL AS THEIR USE IN TREATING TYPE-2 DIABETES | MERCK SHARP & DOHME (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2571876-B1 | SUBSTITUTED SEVEN-MEMBERED HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME (US) | 2016-09-07 | — | — | EP | disclosed |
| US-9422266-B2 | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2016-08-23 | — | — | US | disclosed |
| EP-2680851-B1 | FUSED BICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | MERCK SHARP & DOHME (US) | 2016-08-17 | — | — | EP | disclosed |
| US-9403790-B2 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2016-08-02 | — | — | US | disclosed |
| EP-2538783-B1 | SUBSTITUTED AMINOTETRAHYDROTHIOPYRANS AND DERIVATIVES THEREOF AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME (US) | 2016-06-01 | — | — | EP | disclosed |
| US-20160137622-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME LLC | 2016-05-19 | — | — | US | disclosed |
| WO-2009011872-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| US-7345085-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345085-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070161689-A1 | Indoles having anti-diabetic activity | MERCK SHARP & DOHME LLC | 2007-07-12 | — | — | US | disclosed |
| US-20070161689-A1 | Indoles having anti-diabetic activity | MERCK SHARP & DOHME LLC | 2007-07-12 | — | — | US | disclosed |
| US-20070161689-A1 | Indoles having anti-diabetic activity | MERCK SHARP & DOHME LLC | 2007-07-12 | — | — | US | disclosed |
| US-7186746-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186746-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186746-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050277685-A1 | Indoles having anti-diabetic activity | MERCK SHARP & DOHME LLC | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277685-A1 | Indoles having anti-diabetic activity | GPR119, PPARA, PPARG | PPARG 3/4885PPARA 2/4885CYP2C9 1698/4885 |
| US-20070161689-A1 | Indoles having anti-diabetic activity | GPR119, PPARA, PPARG | PPARG 3/4885PPARA 2/4885CYP2C9 1698/4885 |
| US-20160137622-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | PPARG 2638/4885PPARA 2222/4885CYP2C9 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.